

AD_____

Award Number: W81XWH-11-1-0109

TITLE: Novel CXCR3/CXCR7-Directed Biological Antagonist for Inhibition of Breast Cancer Progression

PRINCIPAL INVESTIGATOR: James W. Lillard, Jr.

CONTRACTING ORGANIZATION: Morehouse School of Medicine
Atlanta, GA 30310-1495

REPORT DATE: September 2012

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.


REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) September 2012		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 1 Sep 2011 - 31 Aug 2012	
4. TITLE AND SUBTITLE Novel CXCR3/CXCR7-Directed Biological Antagonist for Inhibition of Breast Cancer Progression			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-11-1-0109		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) James W. Lillard, Jr. Go cln ¹ lntctf B o uo Qfw			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Morehouse School of Medicine 720 Westview Drive S.W. Atlanta, GA 30310-1495			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Material Command Fort Detrick, Maryland 21702			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT N * * a ~ { æ ä Å à ~ ä Å § â → ' Á Þ æ → æ á b æ Ì € ↔ b \ ã ↔ â \ ↔ ~ ^ Á Û ^ → → ↑ ↔ \ æ ä Å Å					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Docetaxel, a well-established anti-mitotic agent, has been shown in large clinical trials to improve survival and is arguably the standard of care for breast cancer (BrCa) that no longer respond to other therapies. Unfortunately, docetaxel has a number of serious side effects. Therapies that simultaneously prevent BrCa progression and improve docetaxel efficacy are greatly needed. To this end, the numerous anti-apoptotic mechanisms employed by BrCa cells to survive serum-free environments or apoptosis-inducing agents are not entirely known. Chemokines support BrCa progression and cell survival; BrCa cells express CXCR3, CXCR4, and CXCR7, which bind CXCL11 and/or CXCL12. We created a mutant CXCR3/CXCR7 ligand-immunoglobulin fusion protein (mut-CXCL11-Ig) that lacks immunogenic, glycosaminoglycan (GAG)-binding sites but retains the ability to bind, but not activate CXCR3 and CXCR7 receptors. While we had difficulty scaling-up the production of the mut-CXCL11-Ig candidate, we report we have developed a new expression system for production and future animal studies. We also report CXCR3/CXCR4/CXCR7 expression are higher during the G2 phase of BrCa cell cycle, supporting proliferation. CXCL11-Ig reduces chemokine receptor expression, increases docetaxel-driven apoptosis, and reduces CXCL12-dependent cell growth. These studies provide important and new information regarding the cellular and molecular mechanisms, following CXCL11/CXCL12 and CXCR3/CXCR4/CXCR7 interactions, which modulate BrCa progression. Importantly, these studies are the first required to demonstrate the efficacy of mut-CXCL11-Ig for BrCa.					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF: "U"			17. LIMITATION OF ABSTRACT "UU"	18. NUMBER OF PAGES 23	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT "U"	b. ABSTRACT "U"	c. THIS PAGE "U"			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	3
BODY.....	6
Key Research Accomplishments.....	19
Reportable Outcomes.....	19
Conclusion.....	19
References.....	20

INTRODUCTION:

Treatment modalities for breast cancer (BrCa) have improved therapeutic outcomes, but 40% will ultimately die from this disease, highlighting the need for new therapies. Docetaxel is a well-established anti-mitotic chemotherapy that has recently been shown in large clinical trials to improve survival and is arguably the standard of care for BrCa that no longer respond to hormone or Herceptin therapies (i.e., triple negative). However, docetaxel has a number of serious side effects in the majority of patients, due to non-tumor interactions causing nephrotoxicity, neurotoxicity, nausea/vomiting, myelosuppression (thrombocytopenia and neutropenia), hearing loss, and death. Hence, therapies that simultaneously prevent BrCa progression and improve docetaxel efficacy are greatly needed. To this end, the numerous anti-apoptotic mechanisms employed by BrCa cells to survive serum-free environments or apoptosis-inducing agents (e.g., docetaxel) are not entirely known, yet significantly contribute to BrCa's morbidity and mortality. Chemokines have been shown to support BrCa progression and cell survival. BrCa cells express CXCR3, CXCR4, and CXCR7, which if stimulated can support invasion and cell survival. The ligands for CXCR7 are CXCL11, which also binds CXCR3, and CXCL12, which also binds CXCR4. CXCL11 and CXCL12 are expressed by stroma, activated vascular and lymphatic endothelial cells, and tumor associated macrophages that can all support survival or promote invasion of leukocytes (or BrCa cells). Indeed, these CXCR7 ligands are elevated in tissues and serum from patients with a variety of systemic diseases (including BrCa). To solve this problem of CXCR7⁺ BrCa cell stimulation, we created a mutant CXCR3/CXCR7 ligand-immunoglobulin fusion protein (mut-CXCL11-Ig) that lacks immunogenic, glycosaminoglycan (GAG)-binding sites but retains the ability to tightly bind, but not activate CXCR3 and CXCR7 receptors. It is important to note that chemokine receptor signaling following ligand-binding can lead to signaling, which supports cell survival, growth, and/or cell invasion. Previously, we demonstrated our mut-CXCL11-Ig inhibits signaling required for growth and matrix metalloproteinase (MMP) expression by BrCa cells. We also had significantly greater bioavailability (~ 5 days) than compared to native CXCL11 (~30 minutes) or CXCR3 and CXCR7 small molecule antagonists (< 6 hours) without liver toxicity (unlike small molecule inhibitors). These previous studies provided biological and clinical rationales to support the hypothesis that CXCL11 and CXCL12 interactions promote BrCa cell survival and invasion, which can be inhibited with a single biological antagonist - mut-CXCL11-Ig.



Akt binds to the phospholipids produced by PI3K and recruits this kinase to the plasma membrane, where it is activated by phosphorylation. The non-universal role of PI3K in BrCa cell motility, adhesion, and invasion has important implications for the development of new targets against metastatic cancers. Leukocyte migration seems to be mediated in a predominately PI3K-independent and DOCK2-dependent manner (Nombela-Arrieta et al., 2004). While PI3K and (Src and FAK) events have been shown to play a role in cancer cell motility, adhesion, invasion, and survival (Bonaccorsi et al., 2004; Shulby et al., 2004), the potential of PI3K-independent in CXCR7-mediated events remain uncertain. Most likely, PI3K-dependent and -independent pathways may be involved in CXCR7-triggered integrin activation, for subsequent adhesion and invasion.

Chemokine Receptors and Cell Survival

The expression of chemokine receptors on migrating cells may provide these cells with more than directional cues for metastasis. Chemokine receptor signaling may provide a survival advantage once in a foreign environment. These molecular strategies for survival and growth are often the result of using or reprogramming existing physiological pathways (Hendrix et al., 2007). In most cases, survival signals are likely related to the role of chemokine receptor pairs *e.g.*, CXCL12: CXCR4 and CXCL12: CXCR7 in normal development. Other situations for cell survival and proliferation may require redirecting signals from existing migration pathways. For example, studies have shown that metastasized cancer cells have a strong propensity to survive and resist apoptotic stimuli and in some cases, extracellular survival signals can aide or promote cell survival in the “foreign” microenvironment (Nishio et al., 2005).

Unlike other chemokine receptors (*e.g.*, CXCR3 and CXCR4), CXCR7 does not induce Ca^{2+} flux or migration by BrCa cells (Burns et al., 2006). However, CXCR7 promotes cell survival and adhesion (Balabanian et al., 2005). Studies have also shown that chemokine receptor signaling often leads to activation of Akt and subsequent phosphorylation of multiple targets, *e.g.*, glycogen synthase kinase (GSK)- 3β , Forkhead [Drosophila] homolog 1 [rhabdomyosarcoma] (FKHR) and caspase 9 (without caspase 3 induction), which are involved in cell survival (Datta et al., 1999). The current dogma for chemokine receptor signaling involves G α i protein, PI3K, and PLC activation that leads to Ca^{2+} flux. There is no doubt that PI3K can be a key signal after CXCR4 and CXCR3 activation on BrCa cells. The prosurvival molecule Akt binds to the phospholipids produced by PI3K through its PH domain and is recruited to the plasma membrane where it is activated by phosphorylation. Phosphorylated Akt in turn phosphorylates Bad, a pro-apoptotic protein belonging to the Bcl-2 family. When phosphorylated, the cytoplasmic protein 14-3-3 sequesters Bad and apoptosis is inhibited.

A second Akt substrate includes FKHR (Balsara et al., 2001; Schuler et al., 2001). Phosphorylation of FKHR prevents translocation of this protein to the nucleus where it regulates the transcription of genes involved in apoptosis (Biggs et al., 1999). ERK1/2 signaling may also contribute to cell survival through these pathways. For example, studies have shown that ERK1/2 via phosphorylation and inhibition of procaspase-9 and BAD may provide signals for cell survival and proliferation (Allan et al., 2003). Further studies showed ERK1/2 can localize to the nucleus and activate transcription factors involved in cell-cycle regulation and differentiation that promotes cell proliferation (Kyriakis, 2000). Thus, chemokine receptor signaling can activate transcription factors involved in anti-apoptotic mechanisms, cell-cycle regulation, and growth-factor production. These pro-tumorigenic pathways are likely to be particularly important for the ability of metastatic cancer cells to thrive in foreign microenvironments. These studies provide the rationale for my dissertation, which has demonstrated some of the mechanisms of CXCR7 and CXCL12 interactions and subsequent signaling events that promote BrCa cell invasion and survival.

Apoptosis

Apoptosis is an intrinsic cellular defense mechanism against tumorigenic growth, which, if suppressed, can contribute to development of malignancy (Kerr et al., 1972). A wide variety of cytotoxic agents with different intracellular targets can induce the uniform phenotype of apoptosis (Kerr et al., 1972). This implies that the cytotoxic activity of anti-cancer drugs is not solely dependent on specific drug-target interaction, but also on the activity of apoptotic (cell signaling) machinery of the cancer cell (Borner et al., 1995; Denmeade and Isaacs, 1996). There are numerous downstream effectors and transcription factors of Akt, ERK1/2, and tyrosine kinase signaling that can promote cell survival and proliferation. Chemokine signaling often activates NF- κ B, which is commonly downstream of Akt, but can be activated through other pathways, such as PKC (Ye, 2001). NF- κ B dimerizes and translocates to the nucleus of the cell upon activation where it promotes transcription of various apoptosis inhibitors and cell cycle-promoting genes (Karin, 2006). Interestingly, other downstream cell signaling targets through select chemokine receptors activate AKT - NF- κ B to promote the phosphorylation of procaspase-9 and BAD, which inhibit cell signals that dictate apoptosis (Lee et al., 2004). Together, these studies support the notion that CXCR7 (and/or CXCR3) signaling can interfere with apoptosis

signals induced by chemotherapeutic agents, e.g., docetaxel. Hence, the following studies set out a series of hypothesis-driven experiments to test the utility of CXCL11-Ig to block CXCR7 (and CXCR3) involved in BrCa progression.

BODY:

It is important to mention that we encountered **significant obstacles** that delayed completion of the proposed work. First, our move from University of Louisville to Morehouse School of Medicine delayed the start of the project to the Fall of 2011. Secondly, the stable cell line engineered to express wtCXCL11-Ig and mutCXCL11-Ig proteins failed and it took another year to generate new cells to express these proteins. Lastly, the breeding of animals to generate F3 PyMT-Luc (CXCR3^{+/+} or CXCR3^{-/-}) mice has been unsuccessful to date. Our approved Statement of Work laid-out the following tasks, which I have summarized the completion or work currently being performed on the proposed tasks. I apologize for my delay in submitting this progress report, but I had hoped that I could have resolved the above mentioned issues sooner.

Aim One will assess the use of mut-CXCL11-Ig to impede breast tumor growth and MMP expression.

Task 1.1 (complete): Immunogenic residues that also provide CXCL11 the ability to bind GAG were removed to engineer mut-CXCL11-Ig. Mouse anti-mut-CXCL11-Ig humoral and helper T lymphocyte (HTL) responses have been evaluated to confirm that these modifications reduced the immunogenicity of this therapeutic protein.

Task 1.2 and 1.3 (incomplete, but underway, due to low production levels of CXCL11-Ig proteins): 10 mg/kg/week of Control-Ig, nonGAG-binding CXCL11-Ig, or mut-CXCL11-Ig will be used to treat MDA-MB-231-luciferase-positive (luc) as well as MCF-7-luc xenografts. Mammary fat pad of 96 NIH-III mice will be used to orthotopically graft MDA-MB-231-luc and MCF-7-luc cell lines. Breast tumor progression in these mice will be followed non-invasively by *in vivo* imaging. Breast tumors from task 1.2 will be excised to quantify levels of caspase-3/9, Ki67, and MMP expression by histology.

Task 1.4, 1.5, and 1.6 (incomplete and unlikely to complete during funding cycle due to breeding problems): 10 mg/kg/week of Control-Ig, nonGAG-binding CXCL11-Ig, or mut-CXCL11-Ig will be used to treat novel CXCR3^{+/+} and CXCR3^{-/-} MMTV-PyVT (PyMT)-luc mice will be developed and tested to assess the role of CXCR3 in mut-CXCL11-Ig inhibition. Mice spanning 3 generations will be mated to create F3 MMTV-luc that will be subsequently bred with PyMT mice to create PyMT-luc mice. Hence, 440 mice will be bred to create the PyMT-luc mice. Breast tumor progression from task 1.4 will be followed non-invasively imaged to monitor growth. Breast tumors from task 1.4 will be excised to quantify levels of caspase-3/9, Ki67, and MMP expression by histology. Antisera will be collected before sacrifice and will be used to measure mouse anti-chemokine-Ig antibody responses.

Aim Two will characterize the mechanisms of mut-CXCL11-Ig that modulate BrCa progression in the presence and absence of docetaxel.

Task 2.1, 2.2, 2.3, 2.4 (incomplete, but underway, due to low production levels of CXCL11-Ig proteins): MDA-MB-231-luc and MCF-7-luc will be orthotopically implanted into mammary fat pads of NIH-III mice. After tumor formation, 10⁶ photons/sec, mice from task 2.1 will be treated with optimal (10 mg/kg/week) or suboptimal (0.1 mg/kg/week) doses of docetaxel and/or 10 mg/kg/week of Control-Ig, nonGAG-binding CXCL11-Ig, or mut-CXCL11-Ig. 4T1-luc tumor-bearing wildtype mice will be treated with optimal (10 mg/kg/week) or suboptimal (0.1 mg/kg/week) doses of docetaxel and/or 10 mg/kg/week of nonGAG-binding CXCL11-Ig or mut-CXCL11-Ig. Breast tumor progression will be non-invasively imaged to monitor growth.

METHODS

Cell Culture: Human BrCa cell lines, MCF-7 (HTB-22) and MDA-MB-231 (HTB-26), were purchased from American Type Cell Culture. Primary human mammary epithelial cells (HMEC) were obtained from LONZA. HMEC, MCF-7, and MDA-MB-231 cell lines were used for all experiments performed and discussed. HMEC were maintained in MEGM supplemented with 2ml of BPE, 2ml of hydrocortisone, 2 ml of human epithelial growth factor (hEGF), 500 l of insulin, and 2 ml of gentamicin/amphotericin-B. MCF-7 and MDA-MB-231 cells were maintained in IMEM and DMEM (Gibco-Invitrogen) media, respectively, supplemented with 10% FBS (Hyclone-Fisher), without phenol red and 5 µg/ml of penicillin/streptomycin (Gibco) at 37°C with 5% CO₂. Cells were cultured for 3 days in complete culture media then lifted with cell-stripper (Gibco) before being counted with trypan blue by the CellometerTM Auto T4 (Nexcelom Biosciences). Cells were seeded (5 x 10⁵ cells per well) in 6-well plates (Corning-Fisher) containing 1% serum and allowed to acclimate overnight before being treated. Treatments included no addition, 100 ng/ml of CXCL12 (SCYB12; R&D Systems), 100 ng/ml of CXCL12 + 100 ng/ml of pertussis toxin (List Biological Laboratories), 100 ng/ml of CXCL12 + 6 µM

of U73122 (Sigma). Cells were treated with inhibitors one hour prior to the addition of CXCL12 and allowed to incubate for 16 hours. Media was collected and stored at -80°C and used for ELISA-based assays. Cells were used for total RNA isolation using the TRIzol method.

Cell lines & Animals: MDA-MB-231-luc, MCF-7-luc, and 4T1-luc cell lines have been purchased or procured from Caliper/Xenogen or Dr. Patrick Casey, respectively. These cell lines rapidly develop tumors when orthotopically injected in mammary fat pad of Nu/Xid mice. Cells from these xenografts metastasize within 6 weeks on implantation; however, mice that receive MCF-7-luc cells will also require subcutaneous implantation of estrogen pellets (17 β -Estradiol, 0.36 mg/pellet, 60 day release), which will be obtained from Innovative Research of America (Sarasota, FL). Six week old female NIH-bg-nu-Xid mice (NCI-Frederick) will receive 10⁶ of MDA-MB-231-luc or MCF-7-luc cells in 100 μ L of saline by orthotopic mammary fat pad injection under anesthesia with pentobarbital (0.05 mg/g body weight).

Immuno-staining and Morphometric Analysis: After tumor excision, frozen sectioning, sections will be blocked with 2% goat serum and incubated with FITC-conjugated anti-phospho ERK1/2, AKT, and GSK-3 β (BD Pharmingen, R&D Systems, and Santa Cruz Biotechnology), PE-conjugated anti-MMP Abs (R&D Systems and Santa Cruz Biotechnology), and PE-Cy5-conjugated anti-luciferase Abs (Invitrogen). Abs will be applied in serial and the slides will be developed and counterstained with a dilution of DAPI. Linear regression analysis will be used to test the significances of tissue pathology and relevance of phospho ERK1/2, AKT, and GSK-3 β as well as MMP expression. Morphometric analysis of sections will be performed with the aid of Spectrum Plus software (Aperio Technologies). Automated image analysis will be performed Spectrum Plus algorithms for i) Positive Pixel count and Color Deconvolution; ii) Immunohistochemistry Membrane; iii) Immunohistochemistry Nuclear; and iv) Micromet.

Imagestream analysis of protein expression and localization: PE/Cy5 conjugated anti-human CXCR4 antibody (clone#12G5) was purchased from Biolegend, Inc. Polyclonal rabbit anti-CXCR7 antibody was purchased from GeneTex, Inc and conjugated with a donkey-anti-rabbit-FITC antibody (R&D Systems). BrCa cells were seeded in 6-well non-adherent plates at 10⁶ cells/well in media containing 1% FBS and allowed to acclimate 3 hours before treatment. Cells were treated according to the above-mentioned protocols and cell suspensions from each well were taken at 0 and 5 minute time-points and collected for further analysis. Cell suspensions were centrifuged at 200 x g for 10 minutes at 4°C to pellet cells, supernatants were removed and cells were resuspended in 500 μ L of paraformaldehyde (PFA) / phosphate buffered saline (PBS) solution for 10 minutes at RT. Again, cells were centrifuged at 200 x g for 10 minutes at 4°C to pellet cells, supernatants were removed and cells were resuspended in 100 μ L of saponin solution for 30 minutes at RT. Cell suspensions were centrifuged at 200 x g for 10 minutes at 4°C, supernatants were removed and cells were resuspended in 1 μ g (per 10⁶ cells) of primary antibody solution, which consisted of PE-Cy5-conjugated anti-mouse CXCR4, FITC-conjugated anti-mouse CXCR7, Alexa Fluor 488-conjugated or PE-conjugated anti-mouse NF- κ B p65, PE-conjugated anti-mouse ERK1/2 antibodies and/or 7AAD (BD) for 30 min at room temperature. Next, 1ml of fluorescence-activated cell sorting (FACS) buffer (1% bovine serum albumin (BSA) in PBS) to remove any unbound antibodies. Cell suspensions were centrifuged at 200 x g for 10 minutes at 4°C to pellet cells; supernatants were removed and cells were resuspended in 100 μ L of FACS buffer. Analyses were performed using Amnis ImageStream, which allows for flow cytometry-based image acquisition and analysis with six channel (Bright filed, dark filed, and four channel for different fluorochrome). This flow-based image acquisition device is supported by INSPIRE™ software and statistical results gathered using Amnis IDEAS™ software (Amnis Corporation).

The Amnis ImageStream 100 is the first commercially available imaging flow cytometer. It combines advantages of flow cytometry with those of image analysis (digital imagery of each individual cell, calculation of morphological changes, subcellular localization or co-localization of fluorescent probes). Offering several advantages over flow cytometry analysis or microscopic analysis of fluorescently stained cells. Simply put, the ImageStream is essentially a flow cytometer where photomultiplier tubes have been replaced with an array of sensitive charge coupled device (CCD) cameras to capture ~36X images at 100 cells per second.

The images were stored in a compensated image file (CIF) for subsequent analysis using IDEAS software which quantifies change in fluorescent probe pixel intensities in: area of mask in pixels, aspect ratio of mask, weighted aspect ratio of mask, mean intensity of pixels outside of mask, standard deviation of intensity of pixels outside of mask, centroid of mask in horizontal axis, intensity-weighted centroid of mask in horizontal axis, centroid of mask in vertical axis, intensity-weighted centroid of mask in vertical axis, total intensity of image using logical "OR" of all six image masks, variance of intensity of pixels within masks, maximum intensity gradient of pixels within mask, radius mean square (RMS) of intensity gradient of pixels within mask, background-corrected sum of pixel intensities within mask, major axis of mask in pixels, intensity-weighted major axis of mask in pixels, total Intensity of image divided by area of mask, minimum pixel intensity within mask, minor axis of mask in pixels, intensity-weighted minor axis of mask in pixels, angle of major axis relative

to axis of flow, angle of intensity-weighted major axis relative to axis of flow, maximum pixel intensity within mask, number of edge pixels in mask, maximum pixel intensity within large bright spots, sum of pixel intensities within large bright spots, maximum pixel intensity within medium-sized bright spots, sum of pixel intensities within medium-sized bright spots, un-normalized maximum pixel intensity within large bright spots, sum of un-normalized pixel intensities within large bright spots, maximum pixel intensity within small bright spots, sum of pixel intensities within small bright spots, sum of pixel intensities within mask, number of spots detected in image, area of logical "OR" of all six image masks in pixels, camera line readout rate in Hertz at time object was imaged, unique object number, pixel intensity correlation between two images of the same object, and user-defined algebraic combination of imagery and masks, user-defined masks using (erode, dilate, threshold, and boolean combinations), and any boolean combination of user-defined populations.

MTT cell proliferation assay: Breast cancer cells, MCF7 and MDA-MB-231, were treated with different concentrations of CXCL11-IgG fusion proteins IL2ss.CXCL11(1-73). hIgG1Fc (wt) and IL2ss.CXCL11(4-73). hIgG1Fc (mt) and proliferation was measured using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Briefly, cells were seeded in 96-well plates at a density of 10,000 cells per well per 100 μ l media and allowed to adhere for 24 h, followed by addition of wt- and mt-CXCL11-IgG proteins at 0, 50, 100, 200, 400 and 800 ng/ml. Plates in triplicates were then incubated for 24, 48, or 72 h. Each day, 3 hours prior to the end of incubation times, the plates were centrifuged at 200 x g for 5 minutes to pellet potential floating cells, then media were aspirated out of wells and 100 μ l of fresh media containing MTT (5mg/ml) was added to each well. Plates were returned to incubator for an additional 3 h. At the end of incubation time, media was aspirated out of wells, and 200 μ l DMSO was added to each well to solubilize the formazan crystals. Plates were then read with a microplate spectrophotometer at 540 nm. The absorbance of formazan dye solution is in direct proportion to the number of proliferating cells per well.

Flow Cytometry Analysis: CXCR3/CXCR4/CXCR7 expression: Breast cancer cells, MCF7 and MDA-MB-231, were treated with wt- and mt- CXCL11-IgG fusion proteins (500 ng/ml) for 48h and expression of CXCR- 3, 4, and 7 was analyzed using FACS. CXCL11 (100 ng/ml), CXCL12 (100 ng/ml) treated and untreated cells were used as controls. Fluorescein (FITC)-conjugated mouse anti-human CXCR3, Allophycocyanin (APC)-conjugated mouse anti-human CXCR4 and Phycoerythrin (PE)-conjugated mouse anti-human CXCR7 antibody and their respective isotype controls were purchased from R&D Systems. Breast cancer cells were washed three times in phosphate buffered saline (PBS) [supplemented with 1% bovine serum albumin (BSA)] and treated with 1.0 μ g of Fc Block (Pharmingen) per 10^6 cells for 15 min at room temperature. Fc-blocked cells were stained with 1.0 μ g of FITC-, APC-, PE- conjugated mouse anti-human CXCR3, CXCR4, CXCR7 antibodies or respective isotype control antibodies per 10^6 cells at 4°C for 1 h. Subsequently, the cells were washed with 2.0 ml of fluorescence-activated cell-sorting (FACS) buffer (1% BSA in PBS) to remove unbound antibodies. Following washing, 10 μ l of 7-AAD, a nuclear stain, was added to each tube. Next, labeled cells were fixed in 500 μ l of 2% paraformaldehyde solution, and 10^5 cells were analyzed by flow cytometry (FACS ARIA II, BD Biosciences) and data were analyzed using Flow Jo software 8.8.7 for MAC (Tree star Inc., Ashland, OR).

Cell cycle analysis and stage specific expression of CXCR3/CXCR4/CXCR7 in treated and untreated cells: BrCa cells (1×10^6) were treated with wt- and mt- CXCL11-IgG fusion proteins (500 ng/ml) for 48h, and cell cycle distribution was determined by 7-AAD staining using BD FACS ARIA II as described previously. CXCL11 (100 ng/ml), CXCL12 (100 ng/ml) treated and untreated cells were used as controls. Data were analyzed using Flow Jo software 8.8.7 for MAC.

Annexin V/7AAD assay for Apoptosis: For apoptosis assay, BrCa cells (1×10^6) were treated with wt- and mt- CXCL11-IgG fusion proteins (500 ng/ml), CXCL12 (100 ng/ml), and Gemcitabine (6 μ M) for 48h, stained with annexin V-FITC and 7-AAD, according to the manufacturer's protocol (Biolegend, San Diego, CA) and evaluated by BD FACS ARIA II. Untreated cells, and cells treated only with gemcitabine were used as controls. CXCL12 was used as growth factor in all the wells. Data were analyzed using Flow Jo software 8.8.7 for MAC.

RESULTS

Table 1. CXCR7, CXCR4, and CXCR3 antagonist bioavailabilities and toxicities.

Antagonist	Affinity	Serum Half-Life	Toxicities		Reference
			Liver	Cardiac	
CCX451/CCX754	5 nM, CXCR7	< 6 hours	+	-	(Burns et al.) (WO/2005/074645)
AMD3100	12 nM, CXCR4	< 6 hours	+/-	+	(Allen et al.)
AMG487	7 nM, CXCR3	< 6 hours	+	-	(Heise et al.; Wijtmans et al.)
CXCL11	1.4 nM, CXCR3 5 nM, CXCR7	< 12 hours	-	-	(Burns et al.; Cole et al.)
nonGAG-binding mut-CXCL11-Ig	10 nM, CXCR3 7.5 nM, CXCR7	5 days	-	-	Patent Appl. 61/039,226

*Radio-ligand binding was quantified by analyzing CXCR3⁺ and CXCR7⁺ cells in a γ counter (Perkin-Elmer). Data were analyzed and plotted using software (Prism; GraphPad).

Expression of CXCR7 by Breast Tumors: Prior studies in our laboratory and others have shown chemokine receptor expression by various carcinomas (Singh et al., 2004a; Singh et al., 2004b). I confirmed *in vivo* protein expression of CXCR7 by breast tumor tissue. Immunohistochemistry was performed using deparaffinized TMAs stained with DAB (brown), which is representative of CXCR7, and counterstained with hematoxylin (**Figure 3**). CXCR7 expression was elevated in breast tumors staged as T1 (n = 10), T2 (n = 40), T3 (n = 15), and T4 (n = 4) and compared with non-neoplastic breast tissue from the same subject (i.e., n = 69). CXCR7 expression was significantly higher in all breast tumor tissue than compared to benign tissue and highest in T4 > T1, T2, and T3 staged tumor tissue. While expression of CXCR7 in breast tumors did not correlate with stage, a trend of cytoplasmic to nuclear localization of CXCR7 expression was observed when comparing early stage with advanced stage cases, respectively. Amnis ImageStream confirmed strong CXCR7 and CXCR4 protein, cell-surface expression by MCF-7 and MDA-MB-231 cell lines (**Figures 4**). Cell density plots, which analyzed both positive and negative events of each receptor, show the percentage of cells that were positive either for CXCR7, CXCR4, or both receptors. The percent distribution displayed in each cell density plot was based on the intensity of each receptor's protein expression. These findings demonstrate that CXCR4 and CXCR7 protein expression does not precisely correlate with mRNA expression in these cell lines. Further, these results suggest post-transcriptional and/or -translational modification of chemokine receptors may occur, which would not doubt effect their function.

Receptor expression during the cell cycle as well as translocation was also determined using untreated BrCa cells. MCF-7 and MDA-MB-231 cell lines showed high expression of both CXCR7 and CXCR4 in G₂ phase of the cell cycle, with moderate to low expression for S and comparatively low expression during G₀/G₁ phases (**Figure 5**). HMECs showed a similar pattern. Interestingly, this pattern of chemokine receptor expression supports the notion that chemokine receptor signaling during the cell cycle might promote cell survival and proliferation. It is important to mention that while CXCR4 expression is largely confined to the cytoplasm during BrCa progression, the expression of CXCR7 is localized to tumor cell nuclei for advanced BrCa cases. When comparing BrCa cell lines and HMECs, CXCR4 and CXCR7 translocated to the nucleus of cells after CXCL12 stimulation (**Figures 6 and 7**).

CXCL12 is a powerful chemo-attractant that stimulates bi-directional migration, invasion, and survival of breast cancer cells (Huang et al., 2007). I examined whether the interactions of CXCL12-CXCR4/7 are involved in signal-transduction pathways that lead to these events. Previous studies have shown that phosphorylation of ERK1/2 in lung cancer cells is involved in cell migration and invasion (Fernandis et al., 2004). Other studies have shown that NF κ B activation is necessary for cell migration and invasion of other cancer cells (Boukerche et al., 2007). To determine if ERK1/2 and NF κ B are activated by CXCR4/CXCR7 by CXCL12, *in vitro* assays followed by Amnis ImageStream analysis were performed. Untreated HMECs and BrCa cell lines expressed moderate to high protein levels of phosphorylated ERK1/2 and NF κ B in the cytosol (**Figures 8**). After CXCL12 stimulation, both phosphorylated NF κ B and ERK1/2 translocated to the nuclei of BrCa cell lines (**Figures 9**). This demonstrates that detection of CXCL12 by CXCR4 and/or CXCR7

transduces cell signals leading to the activation of both ERK1/2 and NF- κ B and their translocation to the nucleus.

IL2ss.CXCL11.hIgG4Fc sequence

```

                                     IL-2 secretion signal
                                     MetTyrArg MetGlnLeu LeuSerCysLeu
501 TCTGTTCTGC GCCGTTACAG ATCCAAGCTG TGACCCGGCGC CTACCTGAGA TCACCGGCGA AGGAGGGCCA CCATGTACAG GATGCACTC CTGTCTTGCA
                                     EcoRI
                                     CXCL11 (1-73)
101 .IAlaLeuSer LeuAlaLeu ValThrAsnSer PheLysArg GlyArgCysLeu CysIleGly ProGlyVal LysAlaValLys ValAlaAsp
102 TTGCATAAG TCTTGCACCT GTACCAAAAT CGTCCCAATG GTTCAAAAGA GGACGCTGTC TTGTCATAGG CCTGGGGTA AAGCAGTGA AAGTGGCAGA
103 .IleGlnLys AlaSerIleMet TyrProSer AsnAsnCys AspLysIleGlu ValIleIle ThrLeuLys GluAsnLysGly GlnArgCys LeuAsnPro
104 TATTGAGAAA GCTCCATATA TGTACCAAG TAACAACGTG GACAAATAG AAGTATTAT TACCTTGAA GAAATAAAG GACAACGATG CTTAAATCCC
105 human IgG4 Fc (constant region)
106 LysSerLysGln AlaArgLeu IleIleLys LysValGluArg LysAsnPhe ProProCys ProSerCysPro AlaProGlu PheLeuGly GlyProSerVal
107 AAATCGAAGC AAGCAAGGCT TATAATCAAA AAGTGTAAA GAAAGAATTT TCCCCATGCG CCATCATGCC CAGCACCTGA GTTCTGGGG GGACCATCAG
108 .VPhelLeuPhe ProProLys ProLysAspThr LeuMetIle SerArgThr ProGluValThr CysValVal ValAspVal SerGlnGluAsp ProGluVal
109 TCTTCCGTTT CCCCCAAA CCAAGAGCA CTCTCATGAT CTCCCGGACC CCGAGGTCA CCGCTGGGT GTGGACGTG AGCCAGGAAG ACCCCGAGGT
110 .GlnPheAsn TrpTyrValAsp GlyValGlu ValHisAsn AlaLysThrLys ProArgGlu GluGlnPhe AsnSerThrTyr ArgValVal SerValLeu
111 CCAATTCAAC TGGTACGTGG AGCGGTGGA GTGCATAAT CCAAGACAA AGCCGCGGA GGACAGTTC AACAGCACGT ACCGTGTGT CAGCGTCCCT
112 ThrValLeuHis GlnAspTrp LeuAsnGly LysGluTyrLys CysLysVal SerAsnLys GlyLeuProSer SerIleGlu LysThrLys SerLysAlaLys
113 ACCGTCCTGC ACCAGGACTG GCTGAACGCG AAGAGTACA AGTGCAGGT CTCCACAAA GGCTCCCGT CTCTCATGCA GAAACCATC TCCAAAGCCA
114 .LgIyGlnPro ArgGluPro GlnValTyrThr LeuProPro SerArgGlu GluMetThrLys AsnGlnVal SerLeuThr CysLeuValLys GlyPheTyr
115 AAGGCGACC CCGAGAACCA CAGGTGTACA CCTCCGCC ATCCCGAGG AGATGACCA AGAACAGGT CAGCTGACC TGCCTGTGCA AAGGCTCTTA
116 .ProSerAsp IleAlaValGlu TrpGluSer AsnGlyGln ProGluAsnAsn TyrLysThr ThrProPro ValLeuAspSer AspGlySer PhePheLeu
117 CCGCAGCAC ATCCGCTGG AGTGGGAGAG CAATGGGCG CCGAGAACCA ACTCAGAGC CAGCGCTCC GTGCTGGACT CCGACGGCTC CTCTTCTCTC
118 TyrSerArgLeu ThrValAsp LysSerArg TrpGlnGluGly AsnValPhe SerCysSer ValMetHisGlu AlaLeuHis AsnHisTyr ThrGlnLysSer
119 TACAGAGC TACCGTGA CAGAGCAGG TGGCAGGAG GGAATGCTT CTATGCTCC GTATGCTAG AGGCTCTGCA CAACCTACTC ACACAGAAGA
120 BmtI
121 NheI
122 .SLeuSerLeu SerProGly Lys***
1501 GCCTTCCCT GTCTCCGGT AAATGATGC TAGCTGGCCA GACATGATA GATACATTGA TGAGTTTGA CAAACCACAA CTAGATGCA GTGAAAAAAA
```

IL2ss.CXCL11(4-73).hIgG1Fc sequence

```

                                     IL-2 secretion signal
                                     MetTyrArg MetGlnLeu LeuSerCysLeu
501 TCTGTTCTGC GCCGTTACAG ATCCAAGCTG TGACCCGGCGC CTACCTGAGA TCACCGGCGA AGGAGGGCCA CCATGTACAG GATGCACTC CTGTCTTGCA
                                     EcoRI
                                     CXCL11 (4-73)
101 .IAlaLeuSer LeuAlaLeu ValThrAsnSer PheLysArg GlyArgCys LeuCysIleGly ProGlyVal LysAlaVal LysValAlaAsp IleGluLys
102 TTGCATAAG TCTTGCACCT GTACCAAAAT CGTCCCAATG GTTCAAAAGA GGACGCTGTC TTGTCATAGG CCTGGGGTA AAGCAGTGA ATATTAGAAA
103 .AlaSerIle MetTyrProSer AsnAsnCys AspLysIle ThrLeuLys GluValIle ThrLeuLys GluAsnLys GlyGlnArgCys LeuAsnPro LysSerLys
104 AGCCTCCATA ATGTACCAA GTACCAACTG TGACAAATA GAGTGATTA TTACCTGAA AGAATAAAG GACACAGAT GCTTAATCC CAAATCAGAG
105 human IgG1 Fc (constant region)
106 GlnAlaArgLeu IleIleLys LysValGlu ArgLysAsnPhe AspLysThr HisThrCys ProProCysPro AlaProGlu LeuLeuGly GlyProSerVal
107 CAGCAAGC TTATAATCAA AAAATGTGA AGAAGAATTT TGACAAAC TCACACATGC CCACCGTGG CAGCACCTGA ATCTGGGG GGACCGTACG
108 .VPhelLeuPhe ProProLys ProLysAspThr LeuMetIle SerArgThr ProGluValThr CysValVal ValAspVal SerHisGluAsp ProGluVal
109 TCTTCCCTTT CCCCCAAA CCAAGAGCA CCTCATGAT CTCCCGGACC CCGAGGTCA CCGCTGGGT GTGGACGTG AGCCAGGAAG ACCCTGAGGT
110 .LysPheAsn TrpTyrValAsp GlyValGlu ValHisAsn AlaLysThrLys ProArgGlu GluGlnTyr AsnSerThrTyr ArgValVal SerValLeu
111 CCAATTCAAC TGGTACGTGG AGCGGTGGA GTGCATAAT CCAAGACAA AGCCGCGGA GGACAGTTC AACAGCACGT ACCGTGTGT CAGCGTCCCT
112 ThrValLeuHis GlnAspTrp LeuAsnGly LysGluTyrLys CysLysVal SerAsnLys AlaLeuProLys ProlleGlu LysThrLys SerLysAlaLys
113 ACCGTCCTGC ACCAGGACTG GCTGAACGCG AAGAGTACA AGTGCAGGT CTCCACAAA GGCTCCCGT CTCTCATGCA GAAACCATC TCCAAAGCCA
114 .LgIyGlnPro ArgGluPro GlnValTyrThr LeuProPro SerArgGlu GluMetThrLys AsnGlnVal SerLeuThr CysLeuValLys GlyPheTyr
115 AAGGCGACC CCGAGAACCA CAGGTGTACA CCTCCGCC ATCCCGAGG AGATGACCA AGAACAGGT CAGCTGACC TGCCTGTGCA AAGGCTCTTA
116 .ProSerAsp IleAlaValGlu TrpGluSer AsnGlyGln ProGluAsnAsn TyrLysThr ThrProPro ValLeuAspSer AspGlySer PhePheLeu
117 CCGCAGCAC ATCCGCTGG AGTGGGAGAG CAATGGGCG CCGAGAACCA ACTCAGAGC CAGCGCTCC GTGCTGGACT CCGACGGCTC CTCTTCTCTC
118 TyrSerLysLeu ThrValAsp LysSerArg TrpGlnGluGly AsnValPhe SerCysSer ValMetHisGlu AlaLeuHis AsnHisTyr ThrGlnLysSer
119 TACAGAGC TACCGTGA CAGAGCAGG TGGCAGGAG GGAATGCTT CTATGCTCC GTATGCTAG AGGCTCTGCA CAACCTACTC ACACAGAAGA
120 BmtI
121 NheI
122 .SLeuSerLeu SerProGly Lys***
1501 GCCTTCCCT GTCTCCGGT AAATGATGC TAGCTGGCCA GACATGATA GATACATTGA TGAGTTTGA CAAACCACAA CTAGATGCA GTGAAAAAAA
```

Preparation of chemokine-immunoglobulin fusion proteins:

Specific chemokine-Ig fusion polypeptides used in this study include wild-type or mutations are named accordingly to indicate the particular mutation. For example, "mut-" before the CXCL11 (e.g., mut-CXCL11) is indicative of an engineered mutation to CXCL11. Specifically, a truncation of the first three N-terminal amino acids of the mature CXCL11 protein. Further, GAG-binding sites were generated by a chemokine-immunoglobulin fusion polypeptide including in the mutant chemokine polypeptide that has been truncated at the N-terminus to remove residues 1-4 and also mutated to substitute alanines (A) for lysines (K) and histidines (H) within neutral amino acids. Finally, this study we use either human wtCXCL11 or (human-derived) mutCXCL11 fused to Fc constant region of IgG subclass 4 Ig. Subsequently, recombinant vectors comprising nucleic acid molecules that encode the polypeptides disclosed were created and expressed in Chinese

hamster ovary (CHO) cells to express the desired protein. An unexpected result was that expression of these constructs were not stable in CHO cells. Moreover, the GAG-less CXCL11-Ig constructs did not form stable dimers to optimally antagonize CXCR3 and CXCR7 as well as CXCR4/CXCR7 heterodimers. After incurring these problems and several failed attempts, we redesigned the expression vectors and cell lines to a HEK-239 expression system that produced grams per liter of constructs (**Figure 10**). The SDS-PAGE gel analysis confirmed the ~38kDa and ~70kDa size of CXCL11-IgG1Fc under reducing and non-reducing conditions, respectively. Importantly, the GAGless CXCL11-IgG1Fc constructs were expressed, but did not form heterodimers.

CXCL11-IgG1Fc fusion proteins inhibit proliferative of BrCa cells: Both wt- and mt-CXCL11-IgG1Fc fusion proteins inhibited the growth of MCF7 and MDA-MB-231 cells in a dose- and time-dependent manner. The anti-proliferative affect on both cell lines was highest at 72 hours after either wt- and mut-CXCL11-IgG1Fc's. However, the response was significantly higher with wt (GAG) proteins, than compared to mut(GAGless)-proteins. The maximum growth inhibition in MCF-7 and MDA-MB-231 cells was found to be ~51% and ~79%, respectively, with wt-CXCL11-IgG1Fc. However, mut-CXCL11-IgG1Fc induced the greatest growth inhibition in MCF-7 and MDA-MB-231 cell lines at 40% and 73%, respectively (**Figure 11**).

CXCL11-IgG1Fc fusion proteins bind and decrease expression of CXCR3, CXCR4, and CXCR7 by MCF-7 and MDA-MB-231 cells: To determine the binding of CXCL11-IgG1Fc's to CXCR3, CXCR4, and CXCR7, we incubated BrCa cells with wt- or mut- proteins for 48h and analyzed the surface expression of these chemokine receptors by flow cytometry. Untreated, CXCL11-treated and CXCL12-treated cells were used as positive controls to access receptor expression. The expression of receptors (CXCR3/4/7) were significantly decreased following wt-CXCL11-IgG1Fc or mut-CXCL11-IgG1Fc treatment, but compared to controls


(Figure 12). The decrease in expression suggests either i) CXCL11-IgG1Fc's bind to CXCR3, CXCR4, and CXCR7 and prevent receptor internalization and subsequent recycling or ii) CXCL11-IgG1Fc's interactions lead to a significant reduction in CXCR3, CXCR4, and CXCR7.

CXCL11-IgG1Fc fusion proteins induce G2/M phase arrest in BrCa cells: We also investigated the influence of cell cycle stage specific expression of CXCL11, CXCL12, and CXCL11-IgG1Fc's. All conditions shifted and arrested BrCa cells at G2 phase (from G1) (Figure 13, Table 2). wtCXCL11-IgG1 showed the maximum effect on both MCF7 and MDA-MB-231 cell cycle. We also noted that CXCR3, CXCR4, and CXCR7 expression were highest in G2 phase with little or no expression in S and G1 phases of cell cycle (Figure 14). CXCL11-IgG1Fc's were further shown to significantly shift or increase the number of cells in G2 phase in both MCF7 and MDA-MB-231 cells, compared to other culture conditions.

Table 2. Effect of CXCL11, CXCL12, and CXCL11-IgG1Fc fusion proteins on cell cycle distribution in MCF-7 and MDA-MB-231 cells.

Treatment		%G1	%S	%G2/M
Untreated	MCF-7	75.9	7.96	20.4
	MDA-MB-231	87.6	4.13	9.37
wt-CXCL11-IgG	MCF-7	4.18	12.7	99.5*
	MDA-MB-231	26.5	11.2	70.4*
mt-CXCL11-IgG	MCF-7	10.9	21	76.8*
	MDA-MB-231	23	21.1	64.6*
CXCL11	MCF-7	0.066	13.3	85.8*
	MDA-MB-231	17.9	9.64	71.1*
CXCL12	MCF-7	0	9.77	97.6*
	MDA-MB-231	14.4	5.95	79.1*

*BrCa cells were treated with wt- or mt-CXCL11-IgG1Fc (500 ng/mL) for 48 hours, stained with 7AAD, cell cycle distribution was acquired by flow cytometry, and data were analyzed analyzed using FlowJo V.10.






Figure 4. Protein expression and cellular distribution of CXCR4 and CXCR7 by BrCa cell lines. MCF-7 and MDA-MB-231 cells were stained with polyclonal-rabbit anti-CXCR7 antibody conjugated with donkey-anti-rabbit-FITC and PE/Cy5 anti-human CXCR4 antibody. After staining, cells were washed with FACS buffer and analyzed. 7-AAD was used to stain the nucleus and quantified using Amnis ImageStream System. Image analyses were performed using Image Data Exploration Analysis Software (IDEAS). Top panels show density plots of cell populations. Bottom panels from left to right is 7-AAD (red), CXCR7 (green), CXCR4 (purple), and composite respectively.






Figure 5. Cell cycle-dependent CXCR4 and CXCR7 expression by (untreated) primary mammary and BrCa cell lines. HMEC cells as well as MCF-7 and MDA-MB-231 cell lines were stained with polyclonal-rabbit anti-CXCR7 antibody conjugated with donkey-anti-rabbit-FITC and PE/Cy5 anti-human CXCR4 antibody and 7AAD was used to stain cell nuclei. After staining, cells were quantified by Amnis ImageStream and analyzed using Amnis IDEAS. Histograms represent cell populations CXCR4 and CXCR7 intensity.






Figure 8. NFκB and ERK1/2 activation state and cellular distribution by resting (untreated) BrCa cells. MCF-7 and MDA-MB-231 cell lines were stained with Alexa Fluor 488-conjugated mouse anti-NFκB p65 and PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was used to stain the nucleus. Subsequently, images of cells were acquired by Amnis ImageStream and analyzed using IDEAS software. The top panels show the spatial ratio of NFκB, ERK1/2, and nuclei intensities and co-localization as a histogram. The bottom panel shows representative 7-AAD (red), NFκB (green), ERK1/2 (orange), and composite images of the major cell populations.




Figure 9. NFκB and ERK1/2 expression and cytoplasmic to nuclear translocation by CXCL12-treated MCF-7 cells. MCF-7 and MDA-MB-231 cells were stained with Alexa Fluor 488-conjugated mouse anti-NFκB p65 and PE-conjugated mouse anti-ERK1/2 antibodies. 7-AAD was used to stain the nucleus. Subsequently, images of cells were acquired by Amnis ImageStream and analyzed using IDEAS software. The top panels show the spatial ratio of NFκB, ERK1/2, and nuclei intensities and co-localization as a histogram. The bottom panel shows representative 7-AAD (red), NFκB (green), ERK1/2 (orange), and composite images of the major cell populations.




Figure 10. SDS PAGE analysis of HEK-239 cell line expressed CXCL11-IgG1Fc constructs. wtCXCL11-IgG1Fc (A), mutCXCL11-IgG1Fc (B), wtCXCL11-GAGless-IgG1Fc (C), and mutCXCL11-GAGless-IgG1Fc (D) were expressed using human HEK 239 cells. Secreted proteins were captured from serum cell growth medium using protein A columns. Purified proteins were analyzed by NuPAGE Novex Bis-Tris 4-12% gel in both reducing (R) and non-reducing (NR) conditions.




Figure 11. Effect of CXCL11-FcIgG fusion proteins on MCF-7 and MDA-MB-231 cell growth and viability. The effects of MCF-7 and MDA-MB-231 cell viability 24, 48 and 72 hours after wtCXCL11(1-73)-IgG1Fc (Panel A) and mutCXCL11(4-73)-IgG1Fc (Panel B) treatment was measured using a MTT assay. The percent of cell viability was calculated as the percentage of the number of treated cells divided by the number of viable cells before treatment.




Figure 12. CXCL11, CXCL12, wtCXCL11-IgG1Fc and wtCXCL11-IgG1Fc effects on CXCR3, CXCR4, and CXCR7 expression by MCF-7 and MDA-MB-231 cells. Cells were treated with wtCXCL11-IgG, mtCXCL11-IgG, CXCL11 or CXCL12. After 48 hours, cells were stained with FITC- or PE-conjugated anti-CXCR3, -CXCR4, or -CXCR7 antibodies or respective isotype controls. Next, fluorescent events were acquired using a BD FACS ARIA II and data were analyzed using FlowJo V.10. Flow cytometry analysis showing change in expression of chemokine receptors were represented as either shaded (isotype controls) or solid line (stained) histograms.





Figure 13. CXCL11, CXCL12, wtCXCL11-IgG1Fc and wtCXCL11-IgG1Fc effects on MCF-7 and MDA-MB-231 cell cycle. Cells were treated with or without wtCXCL11-IgG, mtCXCL11-IgG, CXCL11 or CXCL12. After 48 hours, cells were stained with 7AAD. Next, fluorescent events were acquired using a BD FACS ARIA II and data were analyzed using FlowJo V.10. Flow cytometry analysis showing change in 7AAD uptake by cell nuclei were represented Watson Pragmatic histograms to denote G1, S, and G2 phases of the cell cycle.



Key Research Accomplishments & Conclusions:

- CXCR7 expression was elevated in breast tumors staged as T1 (n = 10), T2 (n = 40), T3 (n = 15), and T4 (n = 4) and compared with non-neoplastic breast tissue from the same subject (i.e., n = 69).
- While expression of CXCR7 in breast tumors did not correlate with stage, a trend of cytoplasmic to nuclear localization of CXCR7 expression was observed when comparing early stage with advanced stage cases, respectively.
- CXCR4 expression is largely confined to the cytoplasm during BrCa progression, the expression of CXCR7 is localized to tumor cell nuclei for advanced BrCa cases.
- These findings demonstrate that CXCR4 and CXCR7 protein expression does not precisely correlate with mRNA expression in these cell lines.
- Receptor expression during the cell cycle as well as translocation was also determined using untreated BrCa cells. MCF-7 and MDA-MB-231 cell lines showed high expression of both CXCR7 and CXCR4 in G₂ phase of the cell cycle, with moderate to low expression for S and comparatively low expression during G₀/G₁ phases.
- Detection of CXCL12 by CXCR4 and/or CXCR7 transduces cell signals leading to the activation of both ERK1/2 and NF- κ B and their translocation to BrCa cell nuclei.
- CXCL11-IgG1Fc's are ~38kDa and ~70kDa in size of under reducing and non-reducing conditions, respectively. Importantly, the GAGless CXCL11-IgG1Fc construct did not form heterodimers.
- wt-CXCL11-IgG1Fc and mut-CXCL11-IgG1Fc inhibit growth of MCF-7 and MDA-MB-231 cells.
- CXCR3, CXCR4, and CXCR7 were significantly decreased following wt-CXCL11-IgG1Fc or mut-CXCL11-IgG1Fc treatment, than compared to controls.
- CXCL11, CXCL12, and CXCL11-IgG1Fc's shift and/or arrest BrCa cells from G₁ to G₂ phase.

Reportable Outcomes:

PRESENTATIONS: NATIONAL/INTERNATIONAL MEETINGS

Mechanisms Mediated by CXCL12 Signaling through CXCR4 and CXCR7 in Breast Cancer. *American Association for Cancer Research, 101th Annual Meeting*. April 17-21, 2010, Washington, DC.

PATENT

Application Serial #: 13/480,526 (*Utility*)

Filing Date: 5/25/2012 (*United States*)

This invention relates to novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.

Application Serial #: PCT/US12/039550 (*Utility*)

Filing Date: 5/25/2012 (*International*)

This invention relates to novel chemokine-immunoglobulin fusion polypeptides and uses to treat chemokine receptor-mediated disorders, including cancer and inflammatory disorders.

References:

- Docetaxel Allan, L., Morrice, N., Brady, S., Magee, G., Pathak, S., and Clarke, P. (2003). Inhibition of Caspase-9 through Phosphorylation at Thr 125 by ERK-MAPK. *Nat Cell Biol* 5, 647-654.
- Allen, S. J., Crown, S. E., and Handel, T. M. (2007). Chemokine: receptor structure, interactions, and antagonism. *Annu Rev Immunol* 25, 787-820.
- Balabanian, K., Lagane, B., Infantino, S., Chow, K. Y. C., Harriague, J., Moepps, B., Arenzana-Seisdedos, F., Thelen, M., and Bachelier, F. (2005). The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. *Journal of Biological Chemistry* 280, 35760-35766.
- Balsara, B. R., Apostolou, S., Jhanwar, S. C., and Testa, J. R. (2001). AKT plays a central role in tumorigenesis. *Proceeding of National Academy Science of United States of America* 98, 10031-10033.
- Biggs, W. H., 3rd, Meisenhelder, J., Hunter, T., Cavenee, W. K., and Arden, K. C. (1999). Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. *Proc Natl Acad Sci U S A* 96, 7421-7426.
- Bonaccorsi, L., Marchiani, S., Muratori, M., Carloni, V., Forti, G., and Baldi, E. (2004). Singaling mechanisms that mediate invasion in prostate cancer cells. *Annals of the New York Academy of Sciences* 1028, 4693.
- Borner, M. M., Myers, C. E., Sartor, O., Sei, Y., Toko, T., Trepel, J. B., and Schneider, E. (1995). Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3. *Cancer Res* 55, 2122-2128.
- Boukerche, H., Su, Z., Emdad, L., Sarkar, D., and Fisher, P. (2007). Mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma Cells By Activating Nuclear Factor-kappa B. *Cancer Res* 67, 1812-1822.
- Braga, V. (2000). The crossroads between cell-cell adhesion and motility. *Nature Cell Biology* 2, E182-184.
- Burns, J. M., Summers, B. C., Wang, Y., Melikian, A., Berahovich, R., Miao, Z., Penfold, M. E. T., Sunshine, M. J., Littman, D. R., Kuo, C. J., *et al.* (2006). A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 203, 2201-2213.
- Cantrell, D. A. (2001). Phosphoinositide 3-kinase signalling pathways. *Journal of Cell Science* 114, 1439-1445.
- Cole, K. E., Strick, C. A., Paradis, T. J., Ogborne, K. T., Loetscher, M., Gladue, R. P., Lin, W., Boyd, J. G., Moser, B., Wood, D. E., *et al.* (1998). Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. *J Exp Med* 187, 2009-2021.
- Datta, S. R., Brunet, A., and Greenberg, M. E. (1999). Cellular survival: a play in three Akts. *Genes & Development* 13, 2905-2927.
- Denmeade, S. R., and Isaacs, J. T. (1996). Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. *Advances in Pharmacology* 35, 281-306.
- Dustin, M. L., Bivona, T. G., and Philips, M. R. (2004). Membranes as messengers in T cell adhesion signaling. *Nature Immunology* 5, 363.
- Etienne-Manneville, S., and Hall, A. (2002). Rho GTPases in cell biology. *Nature* 420, 629-635.
- Fashena, S. J., and Thomas, S. M. (2000). Signalling by adhesion receptors. *Nature Cell Biology* 2, E225-229.
- Fernandis, A., Prasad, A., Band, H., Klosel, R., and Ganju, R. (2004). Regulation of CXCR4-Mediated Chemotaxis and Chemoinvasion of Breast Cancer Cells. *Oncogene* 23, 157-167.
- Giaugulli, C., Scarpini, E., Ottoboni, L., Narumiya, S., Butcher, E. C., Constantin, G., and Laudanna, C. (2004). RhoA and zeta PKC control distinct modalities of LFA-1 activation by chemokines: critical role of LFA-1 affinity triggering in lymphocyte in vivo homing. *Immunity* 20, 25.

- Heise, C. E., Pahuja, A., Hudson, S. C., Mistry, M. S., Putnam, A. L., Gross, M. M., Gottlieb, P. A., Wade, W. S., Kiankarimi, M., Schwarz, D., *et al.* (2005). Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. *J Pharmacol Exp Ther* 313, 1263-1271.
- Hendrix, M., Seftor, E., Seftor, R., Kasemeier-Kulesa, J., Kulesa, P., and Postovit, L. (2007). Reprogramming Metastatic Tumour Cells with Embryonic Microenvironments. *Nat Rev Cancer* 7, 246-255.
- Huang, Y.-C., Hsiao, Y.-C., Chen, Y.-J., Wei, Y.-Y., Lai, T.-H., and Tang, C.-H. (2007). Stromal Cell-Derived Factor-1 Enhances Motility and Integrin Up-regulation Through CXCR4, ERK and NF- κ B-Dependent Pathway in Human Lung Cancer Cells. *Biochemical Pharmacology* 74, 1702-1712.
- Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., and Yamamoto, T. (1995). Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. *Nature* 377, 539-544.
- Karin, M. (2006). Nuclear Factor - κ B in Cancer Development and Progression. *Nature* 441, 431-436.
- Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *British Journal of Cancer* 26, 239-257.
- Kyriakis, J. (2000). MAP Kinases and the Regulation of Nuclear Receptors. *Science* 288, 1323-1326.
- Laudanna, C., Kim, J. Y., Constantin, G., and Butcher, E. (2002). Rapid leukocyte integrin activation by chemokines. *Immunological Reviews* 186, 37-46.
- Lee, B. C., Lee, T. H., Avraham, S., and Avraham, H. K. (2004). Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1 α in breast cancer cell migration through human brain microvascular endothelial cells. *Molecular Cancer Research: MCR* 2, 327-338.
- Liotta, L. A., and Kohn, E. C. (1995). Angiogenesis: role of calcium-mediated signal transduction. *Cancer Res* 55, 1856-1862.
- Masiero, L., Lapidus, K. A., Ambudkar, I., and Kohn, E. C. (1999). Regulation of the RhoA pathway in human endothelial cell spreading on type IV collagen: role of calcium influx. *Journal of Cell Science* 112, 3205-3213.
- Miyamoto, S., Teramoto, H., Gutkind, J. S., and Yamada, K. M. (1996). Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. *Journal of Cell Biology* 135, 1633-1642.
- Nishio, M., Endo, T., Tsukada, N., Ohata, J., Kitada, S., Reed, J., Zvaifler, N., and Kipps, T. (2005). Nurse-like cells Express BAFF and APRIL, Which Can Promote Survival of Chronic Lymphocytic Leukemia Cells via a Paracrine Pathway Distinct from That of SDF-1 α . *Blood* 106, 1824-1830.
- Nombela-Arrieta, C., Lacalle, R. A., Montoya, M. C., Kunisaki, Y., Megias, D., Marques, M., Carrera, A. C., Manes, S., Fukui, Y., Martinez, A. C., and Stein, J. V. (2004). Differential requirements for DOK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. *Immunity* 21, 429-441.
- Schuler, M., Li, W., Eggers-Sedlet, B., Lee, W., Taylor, P., Fitzgerald, P., Mills, G. B., and Green, D. R. (2001). Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.[comment]. *Journal of Biological Chemistry* 276, 34244-34251.
- Shulby, S. A., Dolloff, N. G., Stearns, M. E., Meucci, O., and Fatatis, A. (2004). CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. *Cancer Res* 64, 4693-4698.
- Singh, S., Singh, U. P., Grizzle, W. E., and Lillard, J. W. (2004a). CXCL12-CXCR4 interactions modulates prostate cancer cell migration, metalloproteinase expression and invasion. *Laboratory Investigation* 84, 1666-1676.
- Singh, S., Singh, U. P., Stiles, J. K., Grizzle, W. E., and Lillard, J. W. (2004b). Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion. *Clin Cancer Res* 10, 8743-8750.

Wijtmans, M., Verzijl, D., Leurs, R., de Esch, I. J. P., and Smit, M. J. (2008). Towards small-molecule CXCR3 ligands with clinical potential. *ChemMedChem* 3, 861-872.

Xue, L., Murray, J. H., and Tolkovsky, A. M. (2000). The Ras/phosphatidylinositol 3-kinase and Ras/ERK pathways function as independent survival modules each of which inhibits a distinct apoptotic signaling pathway in sympathetic neurons. *Journal of Biological Chemistry* 275, 8817-8824.

Ye, R. (2001). Regulation of Nuclear Factor -kB Activation by G-Protein Coupled Receptors. *J Leukocyte Biol* 70, 839-848.